Ascendiant Capital Markets Boosts Envoy Medical (NASDAQ:COCH) Price Target to $8.75

Envoy Medical (NASDAQ:COCH) had its price target boosted by Ascendiant Capital Markets from $8.50 to $8.75 in a research report released on Tuesday, Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Envoy Medical Stock Down 1.9 %

COCH opened at $3.11 on Tuesday. Envoy Medical has a twelve month low of $0.75 and a twelve month high of $11.72. The company has a fifty day simple moving average of $2.49 and a 200 day simple moving average of $3.48.

Envoy Medical (NASDAQ:COCH) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.08 million. Equities research analysts forecast that Envoy Medical will post -1.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Envoy Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of COCH. Virtu Financial LLC bought a new stake in Envoy Medical in the first quarter valued at $55,000. WealthTrust Asset Management LLC acquired a new stake in Envoy Medical during the first quarter valued at approximately $44,000. Finally, Weiss Asset Management LP purchased a new stake in shares of Envoy Medical during the fourth quarter valued at $37,000. 8.59% of the stock is currently owned by institutional investors and hedge funds.

About Envoy Medical

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.